ERK2 (a.a.181-195) Blocking Peptide
€155.00
In stock
SKU
ECM-EX4075
Background:
The ERK1/2 (p44/42) MAPK signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines. Upon stimulation, a sequential three-part MAP kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and a MAP kinase (MAPK). Activation of the MAPKs, ERK1 and ERK2, leads to phosphorylation of activation loop residues Thr-202/Tyr-204 and Thr-185/Tyr-187, respectively. In addition to dual phosphorylation, ERK1 and 2 are autophosphorylated on Thr-207 or Thr-188, respectively. This phosphorylation is required for nuclear translocation of ERK, and leads to phosphorylation of several nuclear proteins involved in cardiac hypertrophy. Mouse models with mutation of Thr-188 in ERK2 show that this site is critical for ERK-mediated cardiac hypertrophy. Thus, phosphorylation of Thr-188 in ERK2 may be important for controlling the nuclear functions of activated ERK1 and ERK2.
Sequence: ERK2 synthetic peptide corresponds to amino acids 181 to 195 from mouse ERK2. This sequence is conserved in human, rat, chicken and fish ERK2, and is highly conserved in other ERK family members, ERK1, ERK5, and ERK7.
Specificity: The peptide is specifically recognized by anti-ERK2 (a.a. 181-195) antibody (EP4071) in ELISA, and has been shown to block the reactivity of EP4071 during Western blot. In addition, the peptide is recommended for use in blocking EP4071 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
The ERK1/2 (p44/42) MAPK signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines. Upon stimulation, a sequential three-part MAP kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and a MAP kinase (MAPK). Activation of the MAPKs, ERK1 and ERK2, leads to phosphorylation of activation loop residues Thr-202/Tyr-204 and Thr-185/Tyr-187, respectively. In addition to dual phosphorylation, ERK1 and 2 are autophosphorylated on Thr-207 or Thr-188, respectively. This phosphorylation is required for nuclear translocation of ERK, and leads to phosphorylation of several nuclear proteins involved in cardiac hypertrophy. Mouse models with mutation of Thr-188 in ERK2 show that this site is critical for ERK-mediated cardiac hypertrophy. Thus, phosphorylation of Thr-188 in ERK2 may be important for controlling the nuclear functions of activated ERK1 and ERK2.
Sequence: ERK2 synthetic peptide corresponds to amino acids 181 to 195 from mouse ERK2. This sequence is conserved in human, rat, chicken and fish ERK2, and is highly conserved in other ERK family members, ERK1, ERK5, and ERK7.
Specificity: The peptide is specifically recognized by anti-ERK2 (a.a. 181-195) antibody (EP4071) in ELISA, and has been shown to block the reactivity of EP4071 during Western blot. In addition, the peptide is recommended for use in blocking EP4071 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
| Is Featured? | No |
|---|
Write Your Own Review